Introduction {#s1}
============

Lung cancer is the leading cause of cancer-related death in the United States and worldwide [@pone.0000426-Jemal1]. Despite recent advances in the treatment of lung cancer, the overall 5-year survival in the United States remains only 15%, highlighting the need for novel treatment strategies.

Lung cancers are currently classified into two major groups depending on histology: small cell lung cancer and non-small cell lung cancer (NSCLC). The latter is comprised of three different subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. The incidence of the adenocarcinoma subtype has been rising and now accounts for \>50% of all cases of lung cancer [@pone.0000426-Gabrielson1]. Standard treatment for metastatic lung cancer involves empiric cytotoxic chemotherapy.

In order to develop specific therapies based upon the genetic makeup of individual NSCLC tumors, we (the Lung Cancer Oncogenome Group at Memorial Sloan-Kettering Cancer Center (MSKCC)) and others have sought to define clinically relevant molecular subsets of lung cancer. For example, we and others have shown that tumors highly sensitive to epidermal growth factor receptor (*EGFR*) tyrosine kinase inhibitors (i.e. gefitinib or erlotinib) often contain dominant mutations in exons which encode a portion of the tyrosine kinase (TK) domain of *EGFR* [@pone.0000426-Lynch1]--[@pone.0000426-Pao1]. Conversely, tumors with somatic mutations in *KRAS*, which encodes a GTPase downstream of EGFR, are resistant to therapy with these drugs [@pone.0000426-Pao2]--[@pone.0000426-Giaccone1]. Furthermore, about half of tumors with acquired resistance to these drugs display a second-site mutation in *EGFR* (Thr790Met) [@pone.0000426-Pao3], [@pone.0000426-Kobayashi1]. Taken together, these data suggest that molecularly defined subgroups of lung cancer indeed exist and can be used to predict sensitivity and resistance to gefitinib and erlotinib. Clinicians in the future may be able to prescribe additional targeted therapies for patients with NSCLC based upon specific molecular characteristics.

At least six EGFR signaling pathway genes have been found to be mutated in NSCLC. While *EGFR* and *KRAS* mutations are detected in ∼10% and 20% of NSCLCs, respectively, somatic mutations have also been identified in *HER2/ERBB2* (∼2%; exons 19 and 20) [@pone.0000426-Stephens1], [@pone.0000426-Shigematsu1] and *HER4* (∼2%, exons 20, 23) [@pone.0000426-Soung1], the lipid kinase *PIK3CA* (∼4%; exon 9) [@pone.0000426-Samuels1], and the serine/threonine kinase *BRAF* (∼2%; exons 11 and 15) [@pone.0000426-Naoki1]--[@pone.0000426-Davies1]. Most of these alterations have been found to be gain-of-function mutations. Except for *PIK3CA* mutations [@pone.0000426-Endoh1], [@pone.0000426-Kawano1], mutations in one of the other five genes are rarely found to be accompanied by a mutation in any of the remaining four, suggesting that they may have functionally equivalent roles in lung tumorigenesis [@pone.0000426-Shigematsu2]. All of these mutations are predominantly found in tumors with adenocarcinoma histology.

To uncover other potential gain-of-function somatic mutations that could have biological and clinical relevance in lung cancer, we performed mutational profiling of a large cohort of lung tumors, mostly adenocarcinomas. Because multiple genes that encode proteins in the EGFR signaling pathway have been found to be mutated in lung adenocarcinomas, we specifically sought to identify potential gain-of-function mutations in gene families in this pathway, i.e. in *ERBB1-4, PIK3CA, AKT1-3, FRAP1, RPS6K1-2, RAS (K-, N-*, and *H-*), *RAF (A-, B-, C-*), *MAP2K1-2*, and *MAPK-1-3*. We extended our studies to include other members of the MAP2K and MAPK gene families. We also examined *FGFR1-4*, because overexpression of FGF ligands in mouse lung epithelia leads to alveolar type II cell hyperplasia and adenomas [@pone.0000426-Clark1]--[@pone.0000426-Zhao1]. All 39 genes have been reported to be expressed in mammalian lung tissues.

Methods {#s2}
=======

Tissue procurement {#s2a}
------------------

Resected tumor and matched normal adjacent lung specimens were obtained with patients\' consent from the Memorial Sloan-Kettering Cancer Center (MSKCC) lung cancer tissue bank via a protocol approved by the Institutional Review Board (protocol \#92-055). At the time of resection, samples were snap-frozen in the operating room in liquid nitrogen and then stored at minus 80°C until the time of use. Specimens were reviewed by a single pathologist (MFZ) for ≥70% tumor content and for histological verification. Clinical information was obtained from existing institutional databases. Some data regarding the mutation status of *EGFR* was previously reported [@pone.0000426-Pao1].

Mutational profiling {#s2b}
--------------------

Tumors selected for analyses were enriched for lung adenocarcinomas but were otherwise randomly selected, based upon availability of tissue. Squamous cell carcinomas were included to fill-in otherwise empty plate wells. No large cell carcinomas were studied.

DNA was extracted from tumors using a kit (DNeasy, Qiagen) or standard phenol extraction. Whole genome amplification (WGA) was performed by Qiagen. High-throughput (96-well plate) bidirectional dideoxynucleotide sequencing of PCR-amplified gene products was performed at the Genome Sequencing Center (Washington University in St. Louis) as per standard protocol (<http://genome.wustl.edu/activity/med_seq/protocols.cgi>). The primer list can be found at: <http://genome.wustl.edu/platforms.cgi?>id = 7.

PolyPhred [@pone.0000426-Nickerson1] and PolyScan [@pone.0000426-Chen1] software were used to generate an initial "automated" report of sequence variations. Tumor sequences were compared against reference sequences listed in the NCBI (RefSeq) database for each respective gene ([**see Supplemental Table S1**](#pone.0000426.s001){ref-type="supplementary-material"}). After visual inspection of the individual forward and reverse chromatograms for confirmation of non-synonymous sequence variations and insertions or deletions (including duplications), a "manual review" list of potential nucleotide changes was produced. Synonymous variants and those with corresponding dbSNP ([www.ncbi.nlm.nih.gov/projects/SNP/](http://www.ncbi.nlm.nih.gov/projects/SNP/)) entries were also excluded.

Mutation verification {#s2c}
---------------------

Putative kinase domain mutations listed in the manual report were subsequently verified at MSKCC by bidirectional sequence analysis of a separate individual PCR product. Variants were deemed somatic if they were found to be absent in matched normal tissue. Primers were designed to detect each individual mutation, using each respective reference sequence and Vector NTI ([**Supplemental Tables S1**](#pone.0000426.s001){ref-type="supplementary-material"} [**and S2**](#pone.0000426.s002){ref-type="supplementary-material"}). All PCR reactions were performed with HotStarTaq Master Mix Kit (Qiagen, Valencia, California), using standard conditions (95°C×15 min; 95°C×30 s, 60°C×30 s, 72°C×60 s, for 36 cycles, then 72°C for 5 minutes, 50 µl reactions). PCR products were purified with a MultiScreen Resist vacuum manifold and PCR~96~ Cleanup Plates (Millipore). Sequencing reactions were performed using Applied Biosystems Version 3.1 Big Dye Terminator chemistry and analyzed on an Applied Biosystems 3730 Sequencer.

Development of "Mutagrator" -- a mutation interpretation tool for tyrosine kinases {#s2d}
----------------------------------------------------------------------------------

To support the interpretation of putative kinase domain mutations, we created a prototype mutation interpretation tool for tyrosine kinases (TKs), called "Mutagrator", located at <http://cbio.mskcc.org/>∼lash/mutagrator/ (freely available to the research community). Mutagrator is a software program which takes curated mutation data from the literature and displays it in the context of a master protein (chosen by the user) and a protein-registered TK multiple domain alignment. In order to create the multiple alignment, we first retrieved 108 human TK gene records from EntrezGene by querying for domain cd00192 [@pone.0000426-Maglott1]. We then extracted TK domains from all 168 protein isoforms corresponding to these genes from Entrez Protein [@pone.0000426-Wheeler1], aligned the domains using the ClustalW program [@pone.0000426-Chenna1], and added additional feature information, including ATP binding residues, activation loop, catalytic loop and substrate binding site boundaries from Conserved Domain Database (CDD) [@pone.0000426-MarchlerBauer1]. All input and output files are available on the Mutagrator website. Currently, curated mutation data is ingested from the Catalogue of Somatic Mutations in Cancer (COSMIC), which was created and is maintained by the Sanger Institute [@pone.0000426-Forbes1]. Collected data includes mutation (amino acid change and position), mutation type (point, insertion, deletion, complex), involved gene, tissue type, cancer type and published source. The version of the database used in this study (v20) consisted of about 30,000 individual mutations in about 1,300 genes, and corresponding to about 3,300 distinct mutations. From these data, Mutagrator produced interlinked, static HTML webpages of two types: master protein pages (for each protein in the TK domain alignment with mutations), and detailed mutation pages (for each protein residue position).

Results {#s3}
=======

We screened coding sequences from 39 genes for mutations in genomic DNA from a total of 261 resected, clinically annotated non-small cell lung cancer (NSCLC) specimens. 90% of tumors were adenocarcinomas, and 10% were squamous cell carcinomas. Clinical characteristics of examined tumors are listed in [**Supplemental Table S3**](#pone.0000426.s003){ref-type="supplementary-material"}, and the exonic coverage of genes is listed in [**Supplemental Table S1**](#pone.0000426.s001){ref-type="supplementary-material"}.

Due to logistical reasons, the mutational analysis was performed in two partially overlapping groups. We first examined genomic DNAs from 217 tumors for mutations in a set of core genes previously reported to harbor mutations in NSCLC, i.e. in *EGFR, HER2, HER4, KRAS, PIK3CA*, and *BRAF* **(** [**Figure 1**](#pone-0000426-g001){ref-type="fig"} **)**. We also profiled *HER3, MAP2K4*, and *FGFR1-4* **(** [**Figure 1**](#pone-0000426-g001){ref-type="fig"} **)**. We then examined 93 WGA-treated DNA tumor samples for mutations in EGFR pathway genes and a set of exploratory genes **(** [**Figure 1**](#pone-0000426-g001){ref-type="fig"} **)**. Ten genes were sequenced in both groups **(** [**Figure 1**](#pone-0000426-g001){ref-type="fig"} **)** to maximize the number of tumors sequenced for the core genes. Eighty percent of the sequence reads in the WGA-treated specimens had a Phred quality score of at least 20 (data not shown), suggesting that most base-calling had an accuracy of 99% [@pone.0000426-Ewing1].

![Genes sequenced in this study.\
The schematic diagram depicts the EGFR signaling pathway. Genes listed in red were sequenced only in genomic DNAs from 217 tumors ("Group 1"). Genes listed in blue were sequenced only in WGA-treated DNA tumor samples ("Group 2"). Genes in black were sequenced in both groups. Gene nomenclature is as reported in GenBank as of December 2006. See Supplemental [Table S3](#pone.0000426.s003){ref-type="supplementary-material"} for clinical characteristics of all tumors sequenced.](pone.0000426.g001){#pone-0000426-g001}

Automatic and manual sequence analyses (see [methods](#s2){ref-type="sec"}) identified 239 putative non-synonymous sequence variations, comprised of 174 different types of variants that differed from published sequences **(** [**Figure 2**](#pone-0000426-g002){ref-type="fig"} **, and [Supplemental Table S1](#pone.0000426.s001){ref-type="supplementary-material"})**. To focus our efforts, we concentrated on further examining the 22 variants (6 types) found in 3 RAS family genes and the 135 variants (99 types) found within exons encoding kinase domains of kinases. The 82 non-kinase domain variants (69 distinct types) have not yet been examined, although none occur at a frequency higher than 2%.

![Schematic of overall results.\
A putative variation was defined as a sequence variation compared to a reference sequence in GenBank. After visual inspection and exclusion of known SNPs and silent changes, there were 239 tumor sequences with a variation representing 174 distinct types of variations. The sequence variations were further divided into three groups: 135 variations (99 distinct types) within exons encoding the kinase domains of respective genes, 82 variations (69 types) in exons encoding areas outside the kinase domains of respective kinase genes, and 22 variations (6 types) in RAS family genes. Non-synonymous variations confirmed by sequence analysis of a 2^nd^ PCR were either somatic mutations or variants found in matched normal tissue (listed in [Supplemental Table S4](#pone.0000426.s004){ref-type="supplementary-material"}). The significance of two novel variants, *ERBB2* (exon 20, Arg784Cys) and *MAPK6* (exon 4, Val262Ile), is unclear, because we could not determine if the variants were also found in DNA from corresponding normal tissue.](pone.0000426.g002){#pone-0000426-g002}

We confirmed 21 of the sequence variations in the *RAS* family. 20 were somatic (all in codons 12 or 13 of exon 2 of *KRAS*), while one in *HRAS* was found in matched normal DNA [**(Supplemental Table S4)**](#pone.0000426.s004){ref-type="supplementary-material"}. The prevalence of *KRAS* mutations in our cohort of lung adenocarcinomas was 12% (20/173). All confirmed somatic mutations were found in adenocarcinomas except for a Gly12Asp mutation in *KRAS* in a squamous cell carcinoma **(** [**Table 1**](#pone-0000426-t001){ref-type="table"} **)**.

10.1371/journal.pone.0000426.t001

###### Clinical characteristics of patients whose tumors contained a somatic mutation.

![](pone.0000426.t001){#pone-0000426-t001-1}

  Tumor                                    Mutation     Age   Gender   Histology         Smoking         Stage
  -------------------------------------- ------------- ----- -------- ----------- --------------------- -------
  *EGFR* mutant                                                                                         
  20t[1](#nt102){ref-type="table-fn"}     exon 19 del   62      F        AWBF             Never           IB
  230t[1](#nt102){ref-type="table-fn"}    exon 19 del   71      F        ADENO            Never           IA
  261t                                    exon 19 del   68      M        AWBF      Former (\>15 pk yr)    IA
  303t                                    exon 19 del   76      M        AWBF      Former (\>15 pk yr)    IB
  317t                                    exon 19 del   77      F        AWBF      Former (≤15 pk yr)     IA
  433t                                    exon 19 del   81      F        AWBF             Never           IB
  428t                                    exon 20 dup   61      M        AWBF      Former (≤15 pk yr)     IA
  5t[1](#nt102){ref-type="table-fn"}       Leu858Arg    53      F        ADENO     Former (≤15 pk yr)     IA
  65t[1](#nt102){ref-type="table-fn"}      Leu858Arg    85      M        AWBF      Former (≤15 pk yr)     IA
  98t[1](#nt102){ref-type="table-fn"}      Leu858Arg    64      F        AWBF      Former (≤15 pk yr)     IA
  134t[1](#nt102){ref-type="table-fn"}     Leu858Arg    68      M        ADENO     Former (≤15 pk yr)     IA
  250t                                     Leu858Arg    45      M        AWBF             Never          IIIA
  251t                                     Leu858Arg    67      F        AWBF      Former (\>15 pk yr)    IA
  *KRAS* mutant                                                                                         
  12t                                      Gly12Val     52      F        ADENO           Current          IB
  70t                                      Gly12Val     58      M        ADENO           Current         IIIA
  86t                                      Gly12Val     58      M        ADENO     Former (\>15 pk yr)    IIB
  109t                                     Gly12Val     78      F        AWBF             Never           IB
  110t                                     Gly12Val     47      M        ADENO           Current          IIB
  404t                                     Gly12Val     70      F        ADENO           Current         IIIB
  6t                                       Gly12Cys     75      M        AWBF      Former (\>15 pk yr)    IA
  29t                                      Gly12Cys     78      F        ADENO     Former (\>15 pk yr)    IB
  64t                                      Gly12Cys     74      M        ADENO     Former (\>15 pk yr)    IIB
  87t                                      Gly12Cys     70      M        AWBF      Former (\>15 pk yr)    IA
  290t                                     Gly12Cys     75      F        ADENO     Former (\>15 pk yr)   IIIB
  357t                                     Gly12Cys     63      F        ADENO     Former (\>15 pk yr)    IIA
  376t[2](#nt103){ref-type="table-fn"}     Gly12Cys     67      F        ADENO     Former (\>15 pk yr)    IB
  439t                                     Gly12Cys     59      M        AWBF      Former (\>15 pk yr)    IA
  1t                                       Gly12Asp     75      F        AWBF      Former (\>15 pk yr)    IV
  37t                                      Gly12Asp     67      F        AWBF      Former (\>15 pk yr)    IB
  L29t                                     Gly12Asp     76      F         SCC             Never           IIB
  67t                                      Gly12Asp     69      M        AWBF      Former (\>15 pk yr)    IA
  68t                                      Gly12Asp     80      M        AWBF      Former (\>15 pk yr)   IIIA
  69t                                      Gly13Cys     66      F        AWBF      Former (\>15 pk yr)    IA
  *PIK3CA* mutant                                                                                       
  376t[2](#nt103){ref-type="table-fn"}     Glu545Lys    67      F        AWBF      Former (\>15 pk yr)    IB
  421t                                     Glu545Lys    80      F        ADENO     Former (\>15 pk yr)    IA
  *BRAF* mutant                                                                                         
  408t                                     Val600Glu    64      M        AWBF      Former (\>15 pk yr)    IB
  *FGFR4* mutant                                                                                        
  410t                                     Glu681Lys    66      F        ADENO           Current         IIIB

Smoking history is defined as never smokers (\<100 lifetime cigarettes), former smokers (quit ≥1 year prior to diagnosis), or current (quit \<1 year prior to diagnosis. Former smokers were further defined as having smoked ≤15 pack years (number of packs of cigarettes smoked per day multiplied by the number of years the person has smoked) or \>15 pack years.

Mutation previously reported (5).

Tumor contained both a *KRAS* and *PIK3CA* mutation. Abbreviations: ADENO, adenocarcinoma; AWBF, adenocarcinoma with bronchioalveolar features (38); SCC, squamous cell carcinoma; dup, duplication; del, deletion. AWBF is equivalent to the WHO classification: adenocarcinoma, mixed subtype, with BAC component (39).

67 of the 135 kinase domain sequence variations were confirmed by analysis of sequence tracings from an independent PCR isolate. 48 variants were also found in corresponding normal samples [**(Supplemental Table S4)**](#pone.0000426.s004){ref-type="supplementary-material"}. Two were of uncertain significance, because we were unable to obtain a PCR product from DNA from matched normal tissue [**(Supplemental Table S4)**](#pone.0000426.s004){ref-type="supplementary-material"}. Of the remaining 17 confirmed non-synonymous somatic variants, 16 were found in genes known to be mutated in NSCLC, i.e. *EGFR, BRAF*, and *PIK3CA* [**(Supplemental Table S4)**](#pone.0000426.s004){ref-type="supplementary-material"}. The prevalence of *EGFR, BRAF*, and *PIK3CA* mutations in lung adenocarcinomas was 6 (13/234), \<1 (1/156), and 2% (2/132), respectively. Clinical characteristics of all tumors containing somatic mutations can be found in [**Table 1**](#pone-0000426-t001){ref-type="table"}. One *PIK3CA* mutation was found in a tumor that also contained a *KRAS* mutation. No other tumor had more than one somatic mutation **(** [**Table 2**](#pone-0000426-t002){ref-type="table"} **)**.

10.1371/journal.pone.0000426.t002

###### Mutations observed in *EGFR, KRAS, BRAF*, and *FGFR4* in lung adenocarcinomas.

![](pone.0000426.t002){#pone-0000426-t002-2}

  \# Samples                            *EGFR*   *KRAS*   *BRAF*   *FGFR4*
  ------------------------------------ -------- -------- -------- ---------
  13[1](#nt105){ref-type="table-fn"}      X        wt       wt       wt
  20[2](#nt106){ref-type="table-fn"}      wt       X        wt       wt
  1                                       wt       wt       X        wt
  1                                       wt       wt       wt        X

Except for one *KRAS* mutant tumor which also contained a *PIK3CA* mutation, no other tumor with a mutation in one of these genes had a mutation in the other 3 genes. X denotes a mutation.

5 EGFR mutations were previously reported (5).

One *KRAS* mutation was found in a squamous cell carcinoma. Abbreviations: wt, wild-type.

In one lung adenocarcinoma specimen from a current smoker, we found a somatic heterozygous G to A mutation at nucleotide position 2041 in exon 16 of *FGFR4* **(** [**Figure 3**](#pone-0000426-g003){ref-type="fig"} **)**. This mutation would lead to substitution of lysine for glutamic acid at position 681 (Glu681Lys), 51 amino acids downstream of the highly conserved DFG motif found in all protein kinases **(** [**Figure 4**](#pone-0000426-g004){ref-type="fig"} **)**. Using our "Mutagrator tool" **(** [**Figure 4**](#pone-0000426-g004){ref-type="fig"}; see [methods](#s2){ref-type="sec"} **)**, we determined that an analogous mutation has been reported in a glioblastoma in *ERBB2* (Glu914Lys) [@pone.0000426-Stephens1]. Moreover, the glutamic acid at position 681 is highly conserved among various kinases **(** [**Figure 4**](#pone-0000426-g004){ref-type="fig"} **)**. The biological significance of the lung *FGFR4* mutation remains to be determined experimentally. In total, this mutation was found in 1 of 158 tumors. We did not identify any other somatic mutations in this tumor **(** [**Table 2**](#pone-0000426-t002){ref-type="table"} **)**.

![Analysis of FGFR4.\
Forward/reverse sequencing chromatograms for the mutation identified in exon 16 of *FGFR4* in tumor and matched normal samples. The nucleotide change is c.2041G\>A, that would lead to substitution of lysine for glutamic acid at position 681.](pone.0000426.g003){#pone-0000426-g003}

![Amino acid alignment of the FGFR4 kinase domain with other tyrosine kinase domains found to be altered in human cancers.\
The DFG motif found in all kinases is underlined. The glutamic acid residue at position 681 in FGFR4 (boxed) is highly conserved amongst the various kinases. Amino acids affected by mutations and reported in the COSMIC (Catalogue of Somatic Mutations in Cancer) database appear in yellow. The analogous Glu914 residue in ERBB2 (boxed) has been found to be mutated in a glioblastoma. Figure adapted from a screenshot of the "Mutagrator" bioinformatics tool developed for this study. The previously reported Pro712Thr mutation in FGFR4 was also identified by the Mutagrator tool but is not shown. See [methods](#s2){ref-type="sec"} for more details.](pone.0000426.g004){#pone-0000426-g004}

Discussion {#s4}
==========

We report a comprehensive sequencing study of major genes in a specific signaling pathway in a sizeable cohort of lung adenocarcinoma tumor specimens. Previous large-scale mutational profiling studies of lung cancer have examined either only the exons encoding the activation loops of receptor tyrosine kinase (RTK) genes (47 of 58 RTK genes) in 119 primary NSCLCs, of which 70 (59%) were lung adenocarcinomas [@pone.0000426-Paez1], or the coding sequences of 518 protein kinases in a relatively limited number of samples, i.e. 26 primary lung neoplasms (7 adenocarcinomas) and seven cancer cell lines (6 adenocarcinomas) [@pone.0000426-Davies2]. Here, we examined a total of 261 tumor samples, predominantly adenocarcinomas, specifically for genetic alterations in genes encoding major signaling proteins in the EGFR signaling pathway. We also determined the status of a select set of other genes potentially relevant to lung tumorigenesis.

Most of the somatic mutations we found have been reported, including mutations in *EGFR, KRAS, BRAF,* and *PIK3CA* [@pone.0000426-Lynch1]--[@pone.0000426-Pao1], [@pone.0000426-Stephens1]--[@pone.0000426-Davies1]. The relative distribution of these mutations in our lung adenocarcinomas matches that observed by others. The frequency of *EGFR* and *KRAS* mutations was slightly lower than other published series, possibly because the mutation detection software that we used went through various stages of development during this project [@pone.0000426-Chen1]. We did not identify any somatic mutations in *HER2* or *HER4*. However, one of two variants of uncertain significance (due to inability to PCR amplify a gene product from matched normal DNA) was located in the kinase domain of *HER2* (Arg784Cys) and has not been previously reported.

We did find a novel mutation (Glu681Lys) in the kinase domain (exon 16) of *FGFR4* in 1 of 158 tumors. This mutation is analogous to the previously reported Glu914Lys kinase domain mutation in *ERBB2* found in a glioblastoma [@pone.0000426-Stephens1]. Glu681 is highly conserved region among various kinases, downstream of the DFG motif. Based on the crystal structure of the related family member FGFR1 tyrosine kinase domain (PDB accession 1FGK) [@pone.0000426-Mohammadi1], the analogous residue (Glu692) appears in close proximity to Ala626 in the TK catalytic loop and Arg661 in the TK activation loop. Since Glu692 is strongly positively charged and Arg661 is strongly negatively charged, the close spatial proximity of these two residues would likely lead to a strong ionic bond and therefore may be functionally important. Extrapolating back to FGFR4, we propose that the Glu681Lys mutation may alter the functional properties of the TK catalytic domain by reversing the charge of residue 681, potentially disrupting an ionic bond with residue Arg650, and thereby disrupting normal function of FGFR4 **(** [**Figure 5**](#pone-0000426-g005){ref-type="fig"} **)**.

![Structural modeling of the FGFR4 Glu681Lys amino acid substitution.\
A. The FGFR4 WT and E681K mutant structures are predicted using the PROTINFO software (38) provided by the (PS)2 server (National Chiao Tung University, Taiwan). These predictions are based on crystallographic structure for FGFR1 tyrosine kinase domain (PDB accession 1FGK) (33), as no FGFR4 structure is available, and visualized using VMD (39). FGFR4 Glu681 (yellow), ATP binding site (pink), activation loop (green) and catalytic loop (white). Glu681 (yellow) is nestled between the TK activation and catalytic loops. B. 3D close-up of the surfaces of Glu681 (yellow), Arg650 (green) in the activation loop, and Ala615 (white) in the catalytic loop. Since Glu681 is strongly negatively charged and Arg650 is strongly positively charged, ionic bonding between these two closely juxtaposed residues may be assumed. C. 3D close-up of the surfaces of mutated Lys681 (orange), Arg650 and Ala615. The glutamic acid to lysine substitution at position 681 could structurally and functionally alter the kinase domain by flipping the charge of residue 681 and disrupting ionic bonds with neighboring residues, particularly the closely juxtaposed Arg650.](pone.0000426.g005){#pone-0000426-g005}

FGFR4 is a monomeric receptor protein tyrosine kinase possessing three immunoglobulin-like domains in the extracellular region. The protein is one of four high-affinity receptors for multiple members of the FGF family of ligands that evoke angiogenic, mitogenic, and differentiation responses in cells [@pone.0000426-Eswarakumar1]. Such ligands, when overexpressed in mouse lung epithelia, stimulate alveolar type II cell hyperplasia and adenoma formation [@pone.0000426-Clark1]--[@pone.0000426-Zhao1]. Interestingly, Davies et al have reported that a lung adenocarcinoma cell line also harbors a non-synonymous mutation in exon 16 of *FGFR4* -- Pro672Thr [@pone.0000426-Davies2]. \[The Davies et al paper referenced *FGFR4* transcript variant 2; we referenced variant 1, so the equivalent mutation would be Pro712Thr.\] Collectively, these data suggest a role for *FGFR4* mutations in a subset of lung adenocarcinomas. The Sanger group also found two other somatic mutations in genes that encode the related family members, *FGFR1* and *FGFR2*, in lung cancer specimens. The described *FGFR1* and *FGFR2* mutations occur outside the kinase domain, but in identical positions to activating germline mutations known to predispose to skeletal dysplasias. Other *FGFR* gene alterations have also been reported in human cancers, although rarely in exons encoding the kinase domain (reviewed in [@pone.0000426-Eswarakumar1]). We plan to characterize the functional consequences of the two reported *FGFR4* mutations and determine their prevalence in independent lung and other tumor specimen banks.

This study has some potential limitations. First, we examined only 39 genes. We did not sequence all related gene family members such as *RPS6KA1-6, MAP2K3*, and *MAP2K7*. This study also did not seek potential mutations in genes encoding adaptor proteins or phosphatases that might affect the ERBB signaling pathway. Second, WGA could have skewed the results by selectively amplifying DNA from normal rather than tumor tissue. However, evaluation of data from multiple assays has established that base-calling discrepancies between amplified and unamplified samples are minimal and not significantly different than that observed after re-sequencing non-amplified samples [@pone.0000426-Bredel1], [@pone.0000426-Paez2]. Consistent with this, in all cases where we found an *EGFR* or *KRAS* mutation in the original non-WGA-treated sample, we also detected the same mutation in the corresponding WGA-treated sample (n = 14; data not shown). Finally, in this initial study, we restricted our verification studies to non-synonymous variants in the exons encoding kinase domains, in view of the clinical significance of known somatic mutations in kinase domains. The 69 types of non-kinase domain sequence variations we identified are currently undergoing confirmation. Nevertheless, the prevalence thus far of non-synonymous somatic mutations per megabase of tumor sequenced in this study was 4.1 (37 total mutations/9Mb). This rate is slightly higher than that found by others in a mutational analysis of ∼13,000 genes in 11 colorectal and 11 breast cancers [@pone.0000426-Sjoblom1].

This study represents an early step towards an understanding of the lung cancer oncogenome. Our results suggest that the majority of gain-of-function mutations within kinase genes in the EGFR signaling pathway may have been identified. We await results from the NCI/NHGRI-sponsored "technical demonstration project" -- a pilot project for The Cancer Genome Atlas initiative, in which approximately 200 highly-curated lung adenocarcinomas are being analyzed for chromosomal gains and losses simultaneously with mutational profiling of about 1000 genes thought to be relevant to lung tumorigenesis. Efforts such as these should contribute towards the identification of the full spectrum of somatic mutations found in lung adenocarcinomas.
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